BRIEF-Pharming Group and Hyupjin get South Korean marketing authorization for Ruconest
Dec 21 (Reuters) - Pharming Group NV :
* Pharming and Hyupjin announce receipt of the South Korean marketing authorization for Ruconest
* Ruconest is approved for treatment of acute angioedema attacks in adult patients with hereditary angioedema HAE
* Says its South-Korean partner Hyupjin will now seek reimbursement for Ruconest in South Korea Source text for Eikon: Further company coverage: (Gdynia Newsroom:)
© Thomson Reuters 2017 All rights reserved.